Last reviewed · How we verify
glutamine alone
Glutamine is a conditionally essential amino acid that serves as a primary fuel source for rapidly dividing cells and supports immune function and gut barrier integrity.
Glutamine is a conditionally essential amino acid that serves as a primary fuel source for rapidly dividing cells and supports immune function and gut barrier integrity. Used for Sepsis or critical illness (Phase 3 investigation).
At a glance
| Generic name | glutamine alone |
|---|---|
| Also known as | Cgroup |
| Sponsor | Air Force Military Medical University, China |
| Drug class | Amino acid supplement |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Sepsis / Intensive Care Medicine |
| Phase | Phase 3 |
Mechanism of action
Glutamine is utilized by immune cells (particularly lymphocytes and macrophages) and enterocytes as a major energy substrate and nitrogen donor for nucleotide synthesis. In critical illness and sepsis, endogenous glutamine production becomes insufficient, and supplementation may preserve gut mucosal integrity, reduce bacterial translocation, and modulate immune responses. This mechanism is particularly relevant in intensive care settings where glutamine depletion is associated with increased infection risk and poor outcomes.
Approved indications
- Sepsis or critical illness (Phase 3 investigation)
Common side effects
- Gastrointestinal tolerance issues
- Hyperammonemia (in hepatic dysfunction)
Key clinical trials
- Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury. (PHASE2)
- Glutamine Combined With Thalidomide in Preventing Radiation-induced Oral Mucositis (PHASE3)
- Effect of Arginine- and Glutamine-based Oral Formulations on Salivary Biomarkers and Clinical Severity of Radiation-induced Oral Mucositis in Head and Neck Cancer: A Randomized Controlled Trial (PHASE2)
- Long-term Follow-up of Diabetic Patients From the GLUTADIAB Study
- Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer. (PHASE3)
- A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R) (PHASE1)
- Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia (PHASE2, PHASE3)
- A Randomized Controlled Trial of Five - Flavor Sophora Flavescens Enteric - Coated Capsules for Radiation - Induced Proctitis After Pelvic Radiotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- glutamine alone CI brief — competitive landscape report
- glutamine alone updates RSS · CI watch RSS
- Air Force Military Medical University, China portfolio CI